Tab 77

ULLMAN, SHAPIRO & ULLMAN, LLP
COUNSELORS AT LAW
299 BROADWAY, SUITE 1700
NEW YORK NY 10007
TEL. (212) 571-0068
FAX. (212) 571-9424
www.usulaw.com
usu@usulaw.com

ROBERT ULLMAN
STEVEN SHAPIRO*
MARC S. ULLMAN

TRADEMARK COUNSEL:
DENNIS H. CAVANAUGH

BUSINESS & TECHNOLOGY COUNSEL:
IRA R. HECHT*&†

OF COUNSEL:
IRVING L. WIESEN

*ADMITTED IN N.Y. & N.J.
&ADMITTED IN FL
†CPA

WASHINGTON AFFILIATE
JAMES M. JOHNSTONE
1775 K STREET, N.W. THIRD FL.
WASHINGTON, D.C. 20006

LONDON AFFILIATES
WEDLAKE BELL
16 BEDFORD STREET
COVENT GARDEN
LONDON WC2E 9HP
ENGLAND

E.U. CORRESPONDENT
LAFILL VAN CROMBRUGGHE
& PARTNERS
VOSSENDREEF 8 BUS 1
B-1180 BRUSSELS
BELGIUM

October 16, 2002

VIA FEDERAL EXPRESS

Mr. Douglas I. Ellsworth, District Director
Food and Drug Administration
New Jersey District Office
Central Region
Waterview Corporate Center
10 Waterview Blvd. 3rd Floor
Parsippany, New Jersey 07054

RE: NVE Pharmaceuticals

Dear Mr. Ellsworth:

We represent NVE Pharmaceuticals ("NVE") in connection with all matters relating to the FDA's inspection of NVE's manufacturing facility, which occurred under a warrant on October 11, 2002. You should be aware that we take this matter very seriously and have consulted with our client at length regarding the proper course of action to be taken at this time. As such, be advised that we have been informed that, upon the order of NVE's President, Mr. Robert Occhifinto, NVE ceased all sales of dietary supplement products bearing the trademarks "Yellow Jackets" and "Black Beauties" (together referred to as the "Products"). Furthermore, the existing inventory of the Products has been placed under quarantine. This action follows Mr. Occhifinto's representation to us that NVE ceased manufacturing "Black Beauties" on September 24, 2002 and "Yellow Jackets" on October 14, 2002.

Following the scheduled FDA inspection tomorrow, we would appreciate the opportunity to sit down with you and discuss this matter further.

Yours truly,

ULLMAN, SHAPIRO & ULLMAN, LLP

Marc S. Ullman, Esq.

EXHIBIT
53

cc: Mr. John Taylor
Director, Office of Enforcement
Office of Regulatory Affairs (HFC-200)
Food and Drug Administration
1350 Piccard Drive, Room 450C
Rockville, Maryland 20850

VIA FEDERAL EXPRESS

Christine Lewis Taylor, Ph.D., Director
Office of Nutritional Products, Labeling, and Dietary Supplements (HFS-800)
Center for Food Safety and Applied Nutrition
Food and Drug Administration
5100 Paint Branch Parkway, Room 4C-096
College Park, Maryland 20740

VIA FEDERAL EXPRESS